Dow Up0.76% Nasdaq Up0.69%




News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


  • Income Statement
  • Balance Sheet
  • Cash Flow

Roche Holding AG (RHHVF)

-Other OTC
290.97 Down 2.53(0.86%) 2:28PM EDT
ProfileGet Profile for:
Roche Holding AG
Grenzacherstrasse 124
Basel, 4070
Switzerland - Map
Phone: 41 61 688 11 11
Fax: 41 61 691 93 91

Index Membership:N/A
Full Time Employees:85,080

Business Summary 

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctorsÂ’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Roche Holding AG

Key Executives 
Dr. Severin Schwan Ph.D., 47
Chief Exec. Officer and Director
Dr. Alan Hippe , 47
Chief Financial Officer and IT Officer
Dr. Gottlieb A. Keller , 60
Gen. Counsel and Corp. Sec.
Mr. Sylvia Ayyobi , 61
Head of HR
Mr. Daniel O'Day , 50
Chief Operating Officer of Pharmaceuticals division
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.